NCT06535841 - A First-in-Human Safety Trial of MTX-474 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

April 24, 2025

Study Completion Date

April 24, 2025

Conditions

Healthy

Interventions

BIOLOGICAL

MTX-474

MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.

OTHER

Placebo

Matching Placebo - Normal Saline

Trial Locations (1)

4006

Nucleus Network, Herston